BriaCell Therapeutics Warrant expiring 2031 (BCTXL) Total Assets by Year
BriaCell Therapeutics Corp. Warrant expiring 2031 closed fiscal year 2026 with $23.6M in total assets, $7.2M in total liabilities and $16.4M in shareholder equity. Total assets rose 8.9% from the prior fiscal year. The table below carries 6 fiscal years, from 2021 to 2026, and the quarters BriaCell Therapeutics Corp. Warrant expiring 2031 has filed alongside them.
Annual figures, oldest first. Point at a bar to read its period.
BCTXL Balance Sheet by Fiscal Year
Figures are as reported in USD. Each change compares the year with the year before it, and each column links to the filing it was taken from.
BCTXL Balance Sheet by Quarter
Figures are as reported in USD. Each change compares the quarter with the same quarter a year earlier.
| Metric | Q4'2610-K | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q | Q2'2410-Q | Q1'2410-Q |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $23.6M+8.9% | $27.1M+59.2% | $33.6M+258.8% | $13.1M+25.5% | $21.6M+268.7% | $17.0M+174.1% | $9.4M-23.4% | $10.4M-44.1% | $5.9M-78.4% | $6.2M-79.1% | $12.2M-64.2% | $18.6M-51.6% |
| Total Liabilities | $7.2M+90.5% | $3.0M-34.3% | $2.7M-53.5% | $3.1M-51.4% | $3.8M-54.3% | $4.6M-62.3% | $5.8M-71.6% | $6.4M-59.9% | $8.3M-73.3% | $12.2M-65.8% | $20.3M-42.7% | $15.9M-43.5% |
| Total Equity | $16.4M-8.3% | $24.1M+93.8% | $30.9M+758.1% | $10.0M+146.8% | $17.9Mn/m | $12.4Mn/m | $3.6Mn/m | $4.0M+48.5% | -$2.4Mn/m | -$6.0Mn/m | -$8.1Mn/m | $2.7M-73.7% |
What total assets means
Total assets is everything the company owns on the balance sheet date, total liabilities is everything it owes, and the difference between them is the equity that belongs to shareholders.
More BriaCell Therapeutics Corp. Warrant expiring 2031 financials
Frequently Asked Questions
BriaCell Therapeutics Corp. Warrant expiring 2031 closed fiscal year 2026 with $23.6M in total assets, $7.2M in total liabilities and $16.4M in shareholder equity.
BriaCell Therapeutics Corp. Warrant expiring 2031 (BCTXL) total assets rose by 8.9% year over year, from $21.6M to $23.6M in fiscal year 2026.
Across the 6 fiscal years this page covers, BriaCell Therapeutics Corp. Warrant expiring 2031 (BCTXL) total assets went from $58.0M in fiscal year 2021 to $23.6M in fiscal year 2026.
BriaCell Therapeutics Corp. Warrant expiring 2031 (BCTXL) reported $23.6M in total assets in Q4 2026. This represents an increase of 8.9% from the same quarter a year earlier.
Total assets is everything the company owns on the balance sheet date, total liabilities is everything it owes, and the difference between them is the equity that belongs to shareholders. This page lists what BriaCell Therapeutics Corp. Warrant expiring 2031 (BCTXL) reported on that line in every period on record.